ATR inhibitor and chemoradiotherapy in oesophageal cancer.
This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).
The study is in setup with a planned opening date of August 2018. A CRUK New Agents Committee grant has been awarded for this study (CRUKD/15/011). Site selection will include Oxford, Leeds & Glasgow.